The WHO has asked countries that have received the vaccine to take appropriate action, according to the statement, but did not specify what appropriate action would be taken. The WHO said the vaccine is effective and there are no safety concerns, but the suspension of production for export will result in the cessation of Covaxin supply. He said the suspension was in response to the results of the WHO inspection for use after the Emergency (EUL) conducted from 14 to 22 March and that the vaccine manufacturer had stated its commitment to suspend production of Covaxin for export. Sign up now for FREE unlimited access to Reuters.com Register Bharat Biotech did not immediately respond to a request for comment outside of business hours. On Friday, the vaccine maker said it was slowing production of Covaxin as demand fell along with falling infections and wider immunization coverage in the country. read more The WHO said the company was “committed to complying with GMP’s shortcomings and developing a remedial and preventive action plan to submit to the Auditor General of India (DCGI) and the WHO”. Sign up now for FREE unlimited access to Reuters.com Register Report by Vishal Vivek in Bengaluru. Edited by David Gregorio Our role models: The Thomson Reuters Trust Principles.
